indications for discharge/admission, 687 management and diagnostic studies, 686 –687 , 687 t treatment, goals of, 685 triage considerations, 686 Carboxyhemoglobinemia, 123 Carcinomas, 910 Cardiac arrest pathways, 45 f signs and symptoms of lack of oxygen/glucose, 47 f Cardiac Arrest Registry to Enhance Survival (CARES), 44 , 57 Cardiac emergencies acquired heart disease, 611 –612 acute heart failure syndromes (AHFS), 610 –611 , 611 t, 612 f acute rheumatic fever, 614 arrhythmic emergencies, 600 –609 bacterial endocarditis, 614 cardiac tamponade, 614 cardiac trauma, 615 –616 cardiomyopathies, 612 –613 congenital heart disease (CHD), 588 –600 Kawasaki disease (KD), 615 myocardial ischemia (MI), 615 myocarditis, 613 patient evaluation with cardiac device, 616 –618 pericarditis, 613 –614 sudden cardiac death, 609 –610 , 611 f therapy goals of, 588 Cardiac infections brucella, 848 Chagas disease, 846 coronaviruses, 846 diphtheria, 847 lymphadenopathy, 847 measles, 847 mumps, 847 –848 Cardiac infectious emergencies acquired heart disease, 611